Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Hutchison China MediTech Limited    HCM   KYG4672N1198

HUTCHISON CHINA MEDITECH LIMITED

(HCM)
  Report
SummaryQuotesNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The group usually releases upbeat results with huge surprise rates.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • Low profitability weakens the company.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Based on current prices, the company has particularly high valuation levels.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
HUTCHISON CHINA MEDITECH LI..0.00%2 604
JOHNSON & JOHNSON-11.70%345 705
ROCHE HOLDING AG2.77%277 060
MERCK & CO., INC-15.48%195 141
NOVARTIS-12.10%187 703
PFIZER, INC.-16.11%181 075
NOVO NORDISK A/S5.61%141 503
BRISTOL-MYERS SQUIBB COMPAN..-13.99%126 110
ELI LILLY AND COMPANY8.18%125 824
AMGEN INC.-13.35%119 572
ASTRAZENECA PLC-8.24%117 896
ABBVIE INC.-15.15%112 508
SANOFI-11.31%110 172
GLAXOSMITHKLINE-16.07%93 854
CHUGAI PHARMACEUTICAL CO., ..0.77%63 605
ALLERGAN PLC-7.13%58 266
More Results
Financials (USD)
Sales 2020 224 M
EBIT 2020 -179 M
Net income 2020 -151 M
Finance 2020 119 M
Yield 2020 -
P/E ratio 2020 -15,7x
P/E ratio 2021 -15,7x
EV / Sales2020 10,1x
EV / Sales2021 8,12x
Capitalization 2 374 M
Upcoming event on HUTCHISON CHINA MEDITECH L
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision